Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

GlaxoSmithKline plc. (12/16/19). "Press Release: Pivotal DREAMM-2 Study Demonstrated a Clinically Meaningful Overall Response Rate with Belantamab Mafodotin (GSK2857916) for Patients with relapsed/refractory Multiple Myeloma". London.

Region Region United States (USA)
Organisations Organisation GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
  Organisation 2 Emory University
Products Product belantamab mafodotin (GSK2857916)
  Product 2 clinical research
Person Person Barron, Hal (GSK 201801– CSO before Alphabet (Calicio) + Roche/Genentech)
     


   
Record changed: 2020-01-13

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for GlaxoSmithKline (GSK) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top